Acute ST-Segment Elevation Myocardial Infarction
Conditions
Interventions
Experimental group:primary Percutaneous Coronary Intervention + Recombinant Streptokinase for Injection (300,000 IU in 5 mL 5% glucose, administered intracoronary, with additional doses allowed as nee
Control group:primary Percutaneous Coronary Intervention
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for acute ST-segment elevation myocardial infarction. 2. The symptoms of STEMI occurred within 12 hours. 3. TIMI thrombus grade >= 2. 4. Age 18 - 75 years old (inclusive), gender not restricted. 5. The research participants voluntarily participated in this study. The participants themselves or their legal representatives signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating females. 2.Patients with severe cardiovascular diseases, including cardiogenic shock, cardiac rupture, and those with suspected aortic dissection, coronary artery dissection, aneurysm or other acute aortic syndromes. 3.Patients with coronary artery disease unsuitable for revascularization. 4.Patients with previously confirmed severe cardiac diseases. 5.Patients receiving cardiopulmonary resuscitation or ventricular fibrillation unconvertible after 3 times of electrical cardioversion. 6.Patients with continuous oral anticoagulant therapy for no less than 3 months. 7.Patients with high bleeding risk or other conditions unsuitable for thrombolytic therapy. 8.Patients with body weight less than 40 kg or more than 200 kg. 9.Patients allergic to recombinant streptokinase or contrast agents. 10.Patients complicated with other systemic diseases, including those with expected survival time less than 1 year due to other illnesses, severe hepatic and renal dysfunction, hematological diseases, acute pancreatitis, diabetes combined with retinopathy, disturbance of consciousness, malignant tumors, etc. 11.Patients deemed ineligible for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-procedure immediate angiography-based index of microcirculatory resistance (caIMR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Corrected TIMI Frame Count (CTFC) immediately after procedure;1-year post-procedure Major Adverse Cardiovascular Events incidence;Length of hospital stay;Proportion of study participants with ST-segment resolution >50% and >70% on ECG at 1 hour after the procedure;Myocardial infarct size, myocardial salvage index (MSI), left ventricular ejection fraction (LVEF), microvascular obstruction, and intramyocardial hemorrhage;Post-procedure immediate TIMI flow grade;Post-procedure immediate angiography-based fractional flow reserve (caFFR); | — |
Countries
China
Contacts
Public ContactLu Yuan
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed